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AbstrAct
Streptococcus pneumoniae is the leading cause of 
the community-acquired pneumonia. The mortality 
rate of invasive pneumococcal infections is high. 
Immunocompromised patients suffering from autoimmune 
inflammatory rheumatic diseases (AIRD) have a high 
risk for acquiring these infections. Protection against 
infection can be improved with vaccination. After using 
polysaccharide vaccines (PPV-23), in July 2013, a 
13-valent conjugate vaccine (PCV-13) was approved 
for adults. Due to its conjugate form, this vaccine is 
the recommended choice in pneumococcal vaccine-
naive patients. PCV-13 is also recommended in patients 
previously receiving PPV-23. Vaccination in AIRD is very 
important and needs deliberate scheduling to coordinate 
with the immunosuppressive therapy. Here, based on 
international and national vaccine guidelines, we provide 
a current review of PPV-23 and PCV-13 vaccines for 
specialists following patients with AIRD.
IntroductIon: the epIdemIology of 
pneumococcal InfectIons
The most common pneumococcal infection, 
such as community-acquired pneumonia 
(CAP), has been a large global challenge for 
healthcare providers. CAP caused by Strep-
tococcus pneumoniae may exert both invasive 
and non-invasive forms. In 2010, pneumonia 
was the most common invasive infection 
accounted for 70% of all cases1. In the USA, 
approximately 4 million cases of CAP are esti-
mated annually among elderly patients1 and 
17%–41% of these cases are caused by S. pneu-
moniae.2 3 The incidence of invasive pneumo-
coccal disease (IPD) depends on geographic 
regions, age group, comorbidities and immu-
nosuppressive conditions. In 2012, the inci-
dence of IPD in Europe was 4.3/100 000, 
the highest rates were seen in Denmark 
(15.8/100 000), Sweden (14.6/100 000) and 
Finland (13.9/100 000). The lowest rates were 
observed in Luxembourg (0.19/100 000), 
Lithuania (0.23/100 000) and Bulgaria 
(0.26/100 000).4 5 In children under the age 
of 1 year, this incidence was 10.9/100 000, 
while in adults aged ≥65 years the frequency 
of confirmed cases was 12.1/100 000 popu-
lation.5 S. pneumoniae is the most frequently 
isolated bacterium in European patients with 
CAP.6 The annual incidence of CAP in adults 
is 1.07–1.20/1000 person-years (PY), while 
in elderly aged ≥65 years it is 14/1000 PY.7 
Comparing the normal adult population to 
special immunocompromised patient groups, 
the incidence is very high in HIV-infected 
patients (12/1000 PY). Among patients 
with autoimmune inflammatory rheumatic 
diseases (AIRD) treated with tumour necrosis 
factor alpha (TNF-α) inhibitors, the inci-
dence is 5.97/1000 PY.7
lower respIratory tract InfectIons In aIrd
Patients with AIRD are immunocompro-
mised and exert increased risk for infec-
tions.8 9 Infection is the major cause of death 
in patients with AIRD. In patients with rheu-
matoid arthritis (RA), after correction for 
age and gender, the mortality of respiratory 
infections is two to five times higher than that 
in the general population. Due to the severity 
of infections, hospital admissions of patients 
with RA are doubled.10 11 Infection is one of 
the most common causes of deaths in systemic 
lupus erythematosus (SLE) and it causes the 
same number of deaths as the active disease 
itself during the first 5 years of illness.12 13 
Gharibdoost et al14 reviewed the mortality of 
2021 Iranian patients with SLE. The retro-
spective analysis indicated that infection was 
the most common cause of death (12.1%) 
between 1991 and 2000. In a systematic review 
published by Falagas et al,15 29% of 5411 
patients with connective tissue disease had 
serious infections leading to death in 24% of 
the cases. The most common disease manifes-
tations were bacteraemia and pneumonia.15
pneumococcal InfectIon Is a vaccIne 
preventable dIsease: Importance of 
capsular serotypes
The polysaccharide capsular serotypes of S. 
pneumoniae are virulence factors responsible 
for invasive infections.16 This bacterium has 
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more than 90 serotypes. In humans, approximately 25–30 
serotypes are responsible for 90% of invasive infectious 
cases.16 The effectivity of vaccine is the reduction in inci-
dence of a disease among those who have been vacci-
nated relative to the incidence in the unvaccinated. The 
efficacy of pneumococcal vaccines highly depends on the 
coverage of the most common serotypes, as well as on 
their immunogenicity.16 17 The prevalence of serotypes is 
variable depending on age, chronic diseases, geographic 
region, administration of pneumococcal vaccines and 
the use of antibiotics.17 For example, in 2010, the most 
common serotypes were 1, 3, 4, 7F, 8, 14, 12F, 19A, 19F 
and 22F in the European Union countries.17 Immuno-
genicity refers to the ability of a vaccine to induce an 
immune response in a vaccinated individual. Protective 
pneumococcal antibody level has been established by the 
working group report of the Basic and Clinical Immu-
nology Interest Section of the American Academy of 
Allergy, Asthma & Immunology: a twofold increase in 
the antibody level (baseline level before vaccination and 
after 4 weeks of vaccination) is an indicator of immune 
responsiveness.18
pneumococcal vaccIne development
In 1977, the first pneumococcal polysaccharide vaccine 
(PPV) approved in the USA included 14 serotypes 
(table 1). Six years later, the number of serotypes 
expanded from 14 to 23.16 The first pneumococcal 
conjugate vaccine (PCV) covering seven serotypes was 
developed in 2000.17 19 During the development of pneu-
mococcal vaccines, the 19A, 1, 7F, 3, 14, 22F, 8, 4, 12F 
and 19F serotypes were most commonly targeted.17 19 Two 
PCVs containing 7 and 10 pneumococcal serotypes were 
licensed in 2000 and 2009, respectively. These vaccines 
were approved only for infants and children.17 19 20 It has 
been established that PCVs exert higher immunogenicity 
compared with PPVs due to T cell-dependent immune 
responses leading to stronger induction of memory 
B cells. PPVs are unable to trigger long-standing immu-
nological memory.20 The 7-serotype PCV has been gradu-
ally removed from the market as it had limited coverage 
of serotypes causing serious pneumococcal infections 
in most developing countries.17 By 2010, a new PCV 
covering 13 serotypes had been developed and was first 
introduced only to children.21 In December 2011, the 
Food and Drug Administration licensed the 13-valent 
PCV for prevention of pneumonia and invasive diseases 
in adults aged ≥50 years.22 23 In June 2012, the Advisory 
Committee on Immunization Practices (ACIP) recom-
mended the routine use of PCV-13 for immunocom-
promised adults.24 25 Finally, the administration of this 
vaccine has been recommended from July 2013 for all 
ages in European countries as recommended by Euro-
pean Medicines Agency.24
The recently used pneumococcal vaccines are indi-
cated in table 2. Most European countries have recom-
mendations on immunisations for pneumococcal disease 
within their childhood vaccination schedule except for 
Croatia, Estonia and Malta. This routine use of PCVs in 
childhood has significantly reduced serotype-specific IPD 
in children.26
pneumococcal vaccInatIon: general consIderatIons
Childhood vaccination impacts the incidence of serious 
invasive infection in the adult population as well. Large 
proportion of pneumococcal vaccination in children 
can reduce transmission of the infection to others, for 
example, adult contacts. This phenomenon is called herd 
immunity: if unvaccinated individuals get in contact with 
vaccinated ones, there is a lower chance to be infected by 
the organism.24 27 After 30-year experience with PPV-23, we 
know that the PPV-23, although it covers a high number of 
serotypes, lacks the booster effect of revaccination, which 
limits its use in all age groups.24 28 As described above, the 
Table 1 Timeline of pneumococcal vaccine development
1911 Starting pneumococcal vaccine research development
1915–1945 Description of chemical structure of pathogen, virulence factors, antigenicity and serotypes. In 
1940 more than 80 serotypes were known.
1977 Introduction of pneumococcal polysaccharide vaccine with 14 serotypes (PPV-14) in USA
1983 Introduction of pneumococcal polysaccharide vaccine with 23 serotypes (PPV-23)
2000 First development of pneumococcal conjugate vaccine with seven serotypes (PCV-7)
2009 Introduction of pneumococcal conjugate vaccine with 10 serotypes (PCV-10) received by European 
Commission authorisation
2010 Introduction of 13-valent pneumococcal conjugate vaccine (PCV-13) for children (6 weeks to 
71 months)
December 2011 First application of PCV-13 in adults ≥50 years
June 2012 ACIP recommendation of PCV-13 for adults aged ≥19 years with immunocompromising conditions
January 2013 PCV-13 for teenagers (6–17 years)
July 2013 EMA recommendation of PCV-13 for all ages
ACIP, Advisory Committee on Immunization Practices; EMA, European Medicines Agency.
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PCV-13 exerts higher immunogenicity and induces B cell 
memory compared with PPV-23.24 27 28 Based on these 
data, the WHO declared and hastened that PCV-13 was 
required to prevent severe pneumococcal disease.24 29–31
pneumococcal vaccInatIon In ImmunocompromIsed 
populatIon
There have been limited data available about immuno-
genicity and safety of PCV-13 administered in immuno-
compromised conditions.
A phase 3, open-label, single-arm study evaluated 
immunogenicity and safety of PCV-13 administered to 
301 pneumococcal vaccine-naive, HIV-infected individ-
uals, who had CD4+ T cell counts ≥200/mL and viral 
load <50 000 copies/mL. Among them, 151 adult patients 
received three doses of PCV-13 followed by one dose of 
PPV-23 after 1 month. In this group, the PCV-13 vaccine 
was effective and well tolerated. Significantly increased 
antibody responses were seen after the first dose of 
PCV-13.32
Pasiarski et al33 investigated response to PCV-13 in 24 
previously untreated adult patients with chronic lympho-
cytic leukaemia (CLL). Patients did not require anti-
cancer therapy. Thirty days after vaccination, specific 
pneumococcal antibody titres showed twofold increase, 
an adequate response to vaccination, in 58.3% of patients 
with CLL.33 Increased serum levels of IgG2 indicated 
effective immunogenicity of the PCV-13 vaccine in 
patients with CLL.33
pneumococcal vaccInatIon In patIents wIth aIrd: 
effIcacy and ImmunogenIcIty of vaccInatIon
Patients with AIRD exert increased risk for pneumo-
coccal infections. AIRD may be associated with secondary 
immunodeficiency and these patients also receive immu-
nosuppressive drugs or biological agents that might 
affect protective immune responses to vaccination.9 10 
There have been limited amount of data with regard to 
the effectiveness and immunogenicity of pneumococcal 
vaccinations in patients with AIRD receiving immunosup-
pressive therapy. In a prospective, multicentre, double-
blind, randomised, placebo-controlled trial, Izumi et al34 
used PPV-23 to vaccinate patients with RA. They found no 
differences in the incidence of pneumonia between corti-
costeroid, methotrexate (MTX) or biologically treated 
patients after a mean of 1.7 years postvaccination.34
There has been one systematic review and meta-anal-
ysis published in 2014 by Hua et al.9 This meta-analysis 
included six studies related to pneumococcal vaccina-
tion. In four of these studies, patients were vaccinated 
by PPV-23 (n=232), while two studies included 114 
patients vaccinated by PCV-7. Responsiveness to pneumo-
coccal vaccines was impaired in patients with RA treated 
with MTX or rituximab, but the response was intact in 
patients receiving TNF-α inhibitors.9 Nevertheless, this 
meta-analysis could not distinguish PPV-23 and PCV-7.9 
Kapetanovic et al35 also reported that PPV-23 response T
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was normal in anti-TNF, but reduced in MTX-treated 
patient. In another study, the anti-interleukin-6 receptor 
antibody tocilizumab, in combination with MTX, slightly 
attenuated humoral responses to PPV-23 in comparison 
to MTX monotherapy.36 Recently, Alten et al37 published 
the results of two multicentre, open-label substudies, 
which evaluated antibody responses to PPV-23 admin-
istered to 125 abatacept-treated patients with RA. This 
study confirmed that the majority of patients with RA 
treated with abatacept had appropriate immune response 
to PPV-23 vaccine, with good safety profile. The concom-
itant use of MTX (irrespective of dose) or corticosteroids 
had no significant impact on the proportion of patients 
achieving protective antibody levels in patients receiving 
abatacept.37
There have been some studies that investigated the 
immunogenicity or effectiveness of PCVs in patients with 
AIRD.38–41 Two studies confirmed that PCV-7, approved 
only for children, was immunogenic in adult patients 
with RA.38 39 Kapetanovic et al39 found reduced antibody 
responses to PCV-7 in MTX-treated patients, while the 
response was intact in patients receiving TNF-α inhibitors. 
Nagel et al40 studied efficacy of a PCV-7 vaccine in adult 
patients with AIRD. They observed statistically non-signif-
icant reduction in the occurrence of serious infections in 
patients with RA and spondyloarthropathy after immu-
nisation with PCV-7. Recently, we have prospectively 
evaluated the immunogenicity of the PCV-13 vaccine in 
patients with RA receiving etanercept. Vaccination with 
PCV-13 was effectively immunogenic and safe. Higher age 
at vaccination was identiﬁed as a predictor of impaired 
antibody response.41 In a recent study, 47 patients with 
SLE receiving belimumab given in addition to standard 
of care therapy were immunised with PCV-13. The study 
confirmed that the efficacy of PCV-13 was not impaired 
by belimumab.42
long-term safety of pneumococcal vaccInes
Based on the literature on pneumococcal vaccine safety, 
there have been no appropriate epidemiological studies 
on serious side effects or postvaccination autoimmunity 
in patients with AIRD. Therefore, data are limited.
Autoimmune inflammatory syndrome induced by adju-
vants (ASIA) or Shoenfeld’s syndrome has been most 
commonly reported after human papilloma and influenza 
vaccination, but there have also been scattered reports 
on Bacillus Calmette-Guerin, diphtheria-tetanus-per-
tussis, hepatitis B and mumps-morbilli-rubella vaccina-
tions.43 Vaccines contain preservatives and adjuvants 
in order to ensure their sterility. Preservatives prevent 
contamination of multidose containers, while adjuvants 
enhance the immunogenicity of the vaccine antigen. PPV 
and PCV contain phenol preservative and aluminium salt 
adjuvant, respectively. The most common adjuvants, such 
as aluminium salts, may cause fever, pain at the injection 
site and malaise. So far there have been no data on pneu-
mococcal vaccine-induced ASIA syndrome.43
Between 2003 and 2014, spontaneous reports of vascu-
litis as an adverse event following immunisation have been 
reported to three international spontaneous reporting 
systems (EudraVigilance, the Vaccine Adverse Event 
Reporting System and VigiBase). The most commonly 
reported pneumococcal vaccine-related event was Kawa-
saki disease. This type of vasculitis occurred mainly in 
children less than 1 year of age. There were no data about 
the type of pneumococcal vaccine triggering vasculitis in 
these reporting systems.44
Altogether 67 patients with cryopyrin-associated peri-
odic syndromes (CAPS) treated with canakinumab were 
followed in the b-CONFIDENT (Clinical Outcomes 
and Safety Registry) global, long-term, prospective, 
observational study. Out of these patients, 19 had pneu-
mococcal vaccination including 15 PPV and 2 PCV-vac-
cinated patients. In two cases, the nature of vaccine was 
unknown. Five PPV-related serious adverse events were 
reported (local inflammation, meningitis, progressive 
cellulitis), while two patients had systemic inflammation 
due to CAPS reactivation. After a period of 10–28 days, 
the adverse events resolved in all patients.45
recommendatIons on pneumococcal vaccInatIon In 
patIents wIth aIrd
Based on the data described above, four sets of clinical 
recommendations have become available on pneumo-
coccal vaccination in AIRD. These include (1) the Euro-
pean League Against Rheumatism (EULAR) recommen-
dations for vaccination in adult patients with autoimmune 
inﬂammatory rheumatic diseases46 47; (2) a WHO position 
paper on pneumococcal vaccines30 31; (3) ACIP recom-
mendations on the use of 13-valent PCV and 23-valent 
PPV for adults with immunocompromising conditions25; 
and (4) Infectious Diseases Society of America (IDSA) 
Clinical Practice Guidelines for vaccination of the immu-
nocompromised host: recommendations for vaccination 
of patients with chronic inflammatory diseases on immu-
nosuppressive medications.48
In 2017, a systematic review of vaccination recom-
mendations for adult immunosuppressed patients was 
published. In this review, authors summarised 12 years of 
Table 3 ACIP recommendation for categories of 
immunosuppression therapy dosing
Immunosuppressive 
therapy
Definition of ‘high-level 
immunosuppression’
Corticosteroids ≥20 mg/day for ≥14 days
Azathioprine >3.0 mg/kg/day
Methotrexate >0.4 mg/kg/week
6-Mercaptopurine >1.5 mg/kg/day
TNF-α inhibitors Any dose
Rituximab Any dose
ACIP, Advisory Committee on Immunization Practices; TNF-α, 
tumour necrosis factor alpha.
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data on American, British, Canadian, Australian, French 
and German recommendations. Patients included 
those with primary immunodeficiency, solid organ and 
haematopoietic stem cell transplantation, inflammatory 
bowel diseases, rheumatic diseases, as well as patients 
who underwent splenectomy, with cancer and HIV.49 
This review recommended pneumococcal vaccinations 
universally following sequential administration protocols 
for patients with AIRD. In rituximab-treated subjects, the 
first pneumococcal vaccine should be administered 2–3 
weeks before initiation of biological treatment.49
These recommendations can now be summarised and 
applied as the currently licensed PCV-13 vaccine has been 
available for immunocompromised patients and appro-
priate advice for sequential vaccination with PPV-23 has 
been developed. Both types of pneumococcal vaccines 
(PPV and PCV) are inactivated vaccines, so there is no 
risk of bacterial reactivation after vaccination. Before 
administration of the pneumococcal vaccine to a patient 
with AIRD, one should determine the optimal timing 
of vaccination, the type of vaccine (PCV-13, PPV-23) to 
be used and the strategy of vaccination (eg, sequential 
application).49
In 2011, EULAR developed the first evidence-based 
recommendations for vaccination in patients with 
AIRD. The committee included experts representing 11 
European countries.46 In 2014, the IDSA published the 
special vaccine recommendations for immunocompro-
mised patients.48 In the recommendation, the defini-
tions of high-level versus low-level immunosuppression 
were established (table 3). High-level immunosuppres-
sion includes more than 20 mg daily use of corticoste-
roids for more than 14 days; more than 3.0 mg/kg daily 
use of azathioprine; more than 0.4 mg/kg weekly use 
of MTX; more than 1.5 mg/kg daily use of 6-mercap-
topurine and any dose of TNF-α inhibitors and ritux-
imab. These categories may determine the protocol of 
vaccination48; however, vaccination is always recom-
mended in these patients. ACIP recommended to admin-
ister pneumococcal vaccinations to adults with planned 
initiation of immunosuppressive therapy or in the status 
of low-level immunosuppression.25
ACIP also reviewed the best available evidence for 
sequential administrations of PCV-13 and PPV-23 to immu-
nocompetent and immunocompromised adults.25 This 
recommendation includes immunocompromised indi-
viduals also including patients with acquired immunode-
ficiency and those receiving immunosuppressive agents. 
The key issue is the determination of optimal intervals 
between the two vaccines. The sequence of administration 
is determined by the high immunogenicity of PCV-13 and 
the high number of covered serotypes of PPV-23. Recent 
studies suggested that the best clinical results could be 
achieved if PCV-13 was administered first to pneumococcal 
vaccine-naive patients. Patients prevaccinated with PPV-23 
should receive PCV-13 after 1 year.25 ACIP does not recom-
mend multiple revaccinations (booster) with PPV-23 in 
the normal population due to insufficient data regarding 
its clinical benefit, particularly the degree and duration of 
protection and safety but only in adults aged ≥19 years with 
immunocompromising conditions. In this group, PPV-23 
vaccination should be repeated at least 5 years after the 
most recent dose of PPV-23, following administration of 
PCV-13.25 Recommendations on sequential PCV-13 and 
PPV-23 vaccination are seen in table 4.
summary
Summarised recommendations of pneumococcal vacci-
nation in patients with AIRD:
 ► The best time to start immunisation is before the ad-
ministration of immunosuppressive therapy (at least 
2–3 weeks before initiation), in stable condition, with-
out disease activity.
Table 4 Sequential administrations of PCV-13–PPV-23 among immunocompromised adults based on ACIP recommendation
Pneumococcal vaccine-naive immunocompromised* adult persons
  First vaccine Interval between two vaccines Second vaccine
PCV-13 ≥8 weeks PPV-23
Previously PPV-vaccinated immunocompromised adult persons ≥65 years
  First vaccine Interval between two vaccines Second vaccine
  PPV-23 ≥1 year PCV-13
Previously received PPV-23 in immunocompromised adults, when aged <65 years
First vaccine before age 65 Interval between first 
PPV-23 and PCV-13
Second vaccine Interval between PCV-13 and 
second  PPV-23
Third vaccine
PPV-23 ≥1 year PCV-13 ≥8 weeks PPV-23
Interval between first and second PPV-23 vaccine: ≥5 years
*Immunocompromised conditions are defined as: congenital or acquired immunodeficiency, human immunodeficiency viral infection, chronic 
renal failure, nephrotic syndrome, leukaemia, lymphoma, Hodgkin disease, generalised malignancy, iatrogenic immunosuppression, solid 
organ transplant, multiple myeloma.
ACIP, Advisory Committee on Immunization Practices; PCV-13, pneumococcal conjugate vaccine with 13 serotypes; PPV-23, pneumococcal 
polysaccharide vaccine with 23 serotypes. 
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 ►  In patients receiving disease-modifying antirheumat-
ic drugs, the timing of vaccination has to be set in 
accordance with the status of immunosuppression. 
Ideally, the vaccine should be performed in patients 
with low-level immunosuppression but the vaccine 
should still be administered even if its efficacy might 
be decreased, so even in patients with high-level im-
munosuppression taking into account the following:
 – There is no requirement of treatment-free inter-
vals before and after immunisation in patients re-
ceiving TNF-α blockers, abatacept or tocilizumab.
 – The vaccination must be started at least 2–3 weeks 
before initiation of rituximab treatment, or 5–7 
months after completion of treatment; if not pos-
sible, at least 6 months after the start and 4 weeks 
before the next course.
 ► Pneumococcal vaccinations have to be administered 
in a sequential manner based on the previous PPV-23 
vaccination status.
 ► The vaccination programme of patients with AIRD 
must be established by approach of multidisciplinary 
team (rheumatologists, infectious disease specialists, 
physicians expert in comorbidity management).
Patients with AIRD are prone to several infections, 
which may be a great challenge for the treating physician. 
Immunogenic PCV or PPV vaccines effectively reduce 
the risk of invasive infectious diseases and pneumonia 
mortality. In order to achieve an optimal response, the 
administrations of PCV-13 and PPV-23 are recommended 
as soon as possible following AIRD diagnosis. These 
vaccines are safe; serious adverse events have rarely been 
reported. There is an important role of all healthcare 
workers to suggest patients with AIRD and their family 
members to manage these vaccinations.
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